Van ECK Associates Corp lifted its stake in shares of Astrazeneca PLC (NYSE:AZN) by 15.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 452,826 shares of the company’s stock after buying an additional 59,615 shares during the quarter. Van ECK Associates Corp’s holdings in Astrazeneca were worth $15,342,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Fisher Asset Management LLC raised its stake in shares of Astrazeneca by 4.7% during the third quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock worth $393,061,000 after purchasing an additional 519,717 shares during the last quarter. Federated Investors Inc. PA raised its position in Astrazeneca by 3.6% in the second quarter. Federated Investors Inc. PA now owns 4,484,770 shares of the company’s stock worth $152,885,000 after acquiring an additional 156,256 shares in the last quarter. Ameriprise Financial Inc. raised its position in Astrazeneca by 7.1% in the third quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock worth $102,643,000 after acquiring an additional 199,519 shares in the last quarter. Voya Investment Management LLC grew its holdings in Astrazeneca by 38.2% in the second quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock valued at $81,661,000 after purchasing an additional 662,481 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Astrazeneca by 5.5% in the second quarter. Dimensional Fund Advisors LP now owns 2,163,183 shares of the company’s stock valued at $73,743,000 after purchasing an additional 112,618 shares during the last quarter. 14.75% of the stock is owned by hedge funds and other institutional investors.
Several research firms have weighed in on AZN. Piper Jaffray Companies reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, August 9th. Cowen reaffirmed a “hold” rating and set a $37.00 price objective on shares of Astrazeneca in a research note on Tuesday, October 17th. Credit Suisse Group raised Astrazeneca from a “neutral” rating to an “outperform” rating in a research note on Monday, October 16th. Investec raised Astrazeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, BMO Capital Markets set a $38.00 price target on Astrazeneca and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $34.20.
Astrazeneca PLC (NYSE:AZN) opened at $32.17 on Tuesday. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $83,172.78, a P/E ratio of 7.84, a price-to-earnings-growth ratio of 3.19 and a beta of 0.72. Astrazeneca PLC has a twelve month low of $25.55 and a twelve month high of $35.60.
Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.57 by $0.55. Astrazeneca had a return on equity of 34.02% and a net margin of 15.90%. The firm had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the prior year, the firm posted $1.32 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. equities research analysts expect that Astrazeneca PLC will post 1.87 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/05/van-eck-associates-corp-buys-59615-shares-of-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.